Skip to main content
. 2016 Sep 30;31(2):310–317. doi: 10.1038/leu.2016.225

Table 2. Outcomes by treatment arms—all estimates are at 5 years except if stated otherwise.

  DA (%) DClo (%) HR/OR, 95% CI P-value
CR 64 58 1.30 (0.98–1.73) 0.07
CRi 6 8    
ORR (CR+CRi) 71 66 1.26 (0.94–1.70) 0.12
Resistant disease 18 24 1.36 (0.97–1.91) 0.08
Induction death 11 11 0.99 (0.64–1.55) 1.0
30-day mortality 9 8 0.98 (0.61–1.57) 0.9
60-day mortality 15 14 0.96 (0.67–1.39) 0.8
Overall survival 14 15 1.04 (0.90–1.21) 0.6
Relapse-free survival 14 15 0.99 (0.83–1.19) 0.9
Cumulative incidence of relapse 78 72 0.93 (0.77–1.13) 0.5
Cumulative incidence of death in CR 8 13 1.47 (0.89–2.43) 0.13
Survival post CR 20 23 0.96 (0.80–1.16) 0.7
Survival post relapse 4 8 0.92 (0.75–1.13) 0.4